Literature DB >> 17466952

Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways.

Catherine Verhaeghe1, Caroline Remouchamps, Benoît Hennuy, Alain Vanderplasschen, Alain Chariot, Sebastien P Tabruyn, Cecile Oury, Vincent Bours.   

Abstract

In cystic fibrosis (CF) patients, pulmonary inflammation is a major cause of morbidity and mortality and may precede bacterial colonization. The aim of the present study was to investigate the molecular mechanisms underlying intrinsic inflammation in cystic fibrosis airways. Using different cystic fibrosis cell models, we first demonstrated that, beside a high constitutive nuclear factor of kappaB (NF-kappaB) activity, CF cells showed a higher activator protein-1 (AP-1) activity as compared to their respective control cells. Gene expression profiles, confirmed by RT-PCR and ELISA, showed over-expression of numerous NF-kappaB and AP-1-dependent pro-inflammatory genes in CF cells in comparison with control cells. Activation of NF-kappaB was correlated with higher inhibitor of kappaB kinase (IKK) activity. In addition, Bio-plex phosphoprotein assays revealed higher extracellular signal-regulated kinase (ERK) phosphorylation in CFT-2 cells. Inhibition of this kinase strongly decreased expression of pro-inflammatory genes coding for growth-regulated proteins (Gro-alpha, Gro-beta and Gro-gamma) and interleukins (IL-1beta, IL-6 and IL-8). Moreover, inhibition of secreted interleukin-1beta (IL-1beta) and basic fibroblast growth factor (bFGF) with neutralizing antibodies reduced pro-inflammatory gene expression. Our data thus demonstrated for the first time that the absence of functional cystic fibrosis transmembrane conductance regulator (CFTR) at the plasma membrane leads to an intrinsic AP-1, in addition to NF-kappaB, activity and consequently to a pro-inflammatory state sustained through autocrine factors such as IL-1beta and bFGF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17466952     DOI: 10.1016/j.bcp.2007.03.019

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  35 in total

Review 1.  Overcoming reduced glucocorticoid sensitivity in airway disease: molecular mechanisms and therapeutic approaches.

Authors:  John A Marwick; Ian M Adcock; Kian Fan Chung
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

2.  Murine guanylate cyclase C regulates colonic injury and inflammation.

Authors:  Kris A Steinbrecher; Eleana Harmel-Laws; Monica P Garin-Laflam; Elizabeth A Mann; Lucas D Bezerra; Simon P Hogan; Mitchell B Cohen
Journal:  J Immunol       Date:  2011-05-09       Impact factor: 5.422

3.  Ets homologous factor (EHF) has critical roles in epithelial dysfunction in airway disease.

Authors:  Sara L Fossum; Michael J Mutolo; Antonio Tugores; Sujana Ghosh; Scott H Randell; Lisa C Jones; Shih-Hsing Leir; Ann Harris
Journal:  J Biol Chem       Date:  2017-05-01       Impact factor: 5.157

4.  Cigarette smoke exposure reveals a novel role for the MEK/ERK1/2 MAPK pathway in regulation of CFTR.

Authors:  Xiaohua Xu; Robert Balsiger; Jean Tyrrell; Prosper N Boyaka; Robert Tarran; Estelle Cormet-Boyaka
Journal:  Biochim Biophys Acta       Date:  2015-02-16

Review 5.  Cystic fibrosis: a mucosal immunodeficiency syndrome.

Authors:  Taylor Sitarik Cohen; Alice Prince
Journal:  Nat Med       Date:  2012-04-05       Impact factor: 53.440

6.  Expression of wild-type CFTR suppresses NF-kappaB-driven inflammatory signalling.

Authors:  Mairi J Hunter; Kate J Treharne; Alexandra K Winter; Diane M Cassidy; Stephen Land; Anil Mehta
Journal:  PLoS One       Date:  2010-07-14       Impact factor: 3.240

7.  The triterpenoid CDDO limits inflammation in preclinical models of cystic fibrosis lung disease.

Authors:  David P Nichols; Assem G Ziady; Samuel L Shank; Jean F Eastman; Pamela B Davis
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-08-21       Impact factor: 5.464

Review 8.  Anti-inflammatory therapies for cystic fibrosis-related lung disease.

Authors:  David P Nichols; Michael W Konstan; James F Chmiel
Journal:  Clin Rev Allergy Immunol       Date:  2008-12       Impact factor: 8.667

9.  Newborn Cystic Fibrosis Pigs Have a Blunted Early Response to an Inflammatory Stimulus.

Authors:  Jennifer A Bartlett; Shyam Ramachandran; Christine L Wohlford-Lenane; Carrie K Barker; Alejandro A Pezzulo; Joseph Zabner; Michael J Welsh; David K Meyerholz; David A Stoltz; Paul B McCray
Journal:  Am J Respir Crit Care Med       Date:  2016-10-01       Impact factor: 21.405

Review 10.  A novel approach to analyze gene expression data demonstrates that the DeltaF508 mutation in CFTR downregulates the antigen presentation pathway.

Authors:  Thomas H Hampton; Bruce A Stanton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-31       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.